Skip to the page

Data / Drug companies / Granules Pharmaceuticals Inc.

Granules Pharmaceuticals Inc.: 147 products in the FDA NDC directory, labeler code 70010

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Granules Pharmaceuticals Inc. (labeler code 70010) lists 147 products in the FDA National Drug Code Directory, covering 45 finished drugs by generic name. By type: 129 prescription drugs, 10 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 18, 2026.

The request: Watch Granules Pharmaceuticals Inc. (FDA labeler code 70010): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70010
Products in commercial distribution
147
Packages
339
Finished drugs by generic name
45
Prescription products
129
Over the counter products
10
Controlled substance products
Schedule II 50, Schedule III 3
Flagged as original packager
64 of 64 products that carry the flag
Started marketing in the last 12 months
6
Earliest marketing start
May 25, 2018
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)13793.2%
Drugs for further processing85.4%
Over the counter monograph drugs21.4%

Products by type

TypeProductsShare
Prescription drugs12987.8%
Over the counter drugs106.8%
Drugs for further processing85.4%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet4228.6%
Capsule, extended release2517%
Capsule2013.6%
Tablet, film coated1912.9%
Tablet, extended release149.5%
Tablet, film coated, extended release74.8%
Tablet, chewable64.1%
Tablet, coated42.7%
Solution42.7%
Tablet, delayed release21.4%
For solution21.4%
Capsule, delayed release21.4%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Ibuprofen70010-068Tablet, film coatedDrugs for further processingFebruary 18, 2026
Ibuprofen70010-068Tablet, film coatedGeneric drugs (ANDA)February 18, 2026
Ibuprofen70010-067Tablet, film coatedGeneric drugs (ANDA)February 18, 2026
Ibuprofen70010-067Tablet, film coatedDrugs for further processingFebruary 18, 2026
Ibuprofen70010-066Tablet, film coatedGeneric drugs (ANDA)February 18, 2026
Ibuprofen70010-066Tablet, film coatedDrugs for further processingFebruary 18, 2026
Cetirizine hydrochloride - HIVES70010-293Tablet, coatedGeneric drugs (ANDA)September 2, 2025
Glycopyrrolate Oral Solution70010-106SolutionGeneric drugs (ANDA)August 19, 2025
Bupropion hydrochloride70010-127Tablet, film coated, extended releaseGeneric drugs (ANDA)March 31, 2025
Bupropion hydrochloride70010-126Tablet, film coated, extended releaseGeneric drugs (ANDA)March 31, 2025
Bupropion hydrochloride70010-125Tablet, film coated, extended releaseGeneric drugs (ANDA)March 31, 2025
Lisdexamfetamine dimesylate70010-212CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-211CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-210CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-209CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-208CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-207CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-206CapsuleGeneric drugs (ANDA)January 29, 2025
Lisdexamfetamine dimesylate70010-219Tablet, chewableGeneric drugs (ANDA)December 17, 2024
Lisdexamfetamine dimesylate70010-218Tablet, chewableGeneric drugs (ANDA)December 17, 2024
Lisdexamfetamine dimesylate70010-217Tablet, chewableGeneric drugs (ANDA)December 17, 2024
Lisdexamfetamine dimesylate70010-216Tablet, chewableGeneric drugs (ANDA)December 17, 2024
Lisdexamfetamine dimesylate70010-215Tablet, chewableGeneric drugs (ANDA)December 17, 2024
Lisdexamfetamine dimesylate70010-214Tablet, chewableGeneric drugs (ANDA)December 17, 2024
Dofetilide 0.5mg70010-026CapsuleGeneric drugs (ANDA)November 14, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.